,test_validation,age_max,state,sex,age,isotypes,serum_pos_prevalence,sampling_end_date,denominator_value,sampling_method,specificity,age_min,estimate_name,sensitivity,specimen_type,test_type,numerator_value,sampling_start_date,population_group,estimate_grade,subgroup_specific_category,antibody_target,subgroup_var,county,publication_date,included,source_type,include_in_srma,jbi_1,source_name,ind_sp_n,ind_eval_link,lead_organization,jbi_3,jbi_7,country,jbi_4,ind_eval_lab,jbi_5,test_linked_uid,jbi_6,ind_se,measure_of_age,age_variation,study_name,number_of_males,summary,jbi_9,number_of_females,organizational_author,ind_se_n,jbi_8,ind_sp,average_age,jbi_2,age_variation_measure,source_publisher,study_type,url,first_author,airtable_record_id,overall_risk_of_bias,zotero_citation_key,is_unity_aligned,test_name,test_manufacturer,date_created,last_modified_time,test_not_linked_reason,sensspec_from_manufacturer,dashboard_primary_estimate,academic_primary_estimate,sp_n,city,se_n,sample_frame_info,numerator_definition,pop_adj,subgroup_cat,seroprev_95_ci_upper,seroprev_95_ci_lower,isotype_comb,test_adj,case_population,deaths_population,case_count_0,case_count_neg9,case_count_neg14,death_count_plus4,death_count_plus11
0,Validated by independent authors/third party/non-developers,30.0,['Michigan'],All,Adults (18-64 years),['IgG'],0.07200000000000001,2020-07-08,111,Self-referral,0.99,18.0,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem_18-30years,1.0,Serum,CLIA,8.0,2020-06-08,Health care workers and caregivers,Local,18-30 years,['NR'],Age,"Washtenaw, Wayne, Livingston",2020-09-23,True,Journal Article (Peer-Reviewed),True,Yes,Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work Environment,163,,Veterans Affairs Ann Arbor Healthcare System,Yes,Yes,United States of America,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Groups,,200923_AnnArbor_VeteransAffairsAnnArborHealthcareSystem,489.0,Veterans Affairs Ann Arbor Healthcare system studied employees of a Veterans Affairs healthcare system (n=1476) in Ann Arbor Michigan and found a seroprevalence of 4.9% (95% CI 3.8%-6.1%).,No,944.0,,73,No,1.0,"18-30 (n=111, 7.5%); 31-40 (n=372, 25.2%); 41-50 (n=392, 26.6%); 51-60 (n=406, 27.5%); >60 (n=149, 10.1%); No response (n=46, 3.1%)/",No,,Infection control and hospital epidemiology,Cross-sectional survey ,https://dx.doi.org/10.1017/ice.2020.1220,Dimcheff,rec00Pbuu4BwXiBxw,Moderate,dimcheff_seroprevalence_nodate,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2020-11-23,2021-06-16,,,,,,,,,,,,,,,,,,,,,,
1,,,,All,Multiple groups,['Not reported'],0.14,2020-06-10,650000,Unclear,0.98,0.0,200611_Russia_NationalCouncilCombatingCoronavirus_GenPop,0.9500000000000001,,,,,Household and community samples,National,,['NR'],Primary Estimate,,2020-06-10,True,News and Media,True,Yes,1 in 7 Russians Have ‘Coronavirus Immunity’ – Official,,,Russian National Council for Combating Coronavirus,Yes,Yes,Russian Federation,No,,Unclear,,Yes,,,,200611_Russia_NationalCouncilCombatingCoronavirus,,The Russian National Council Combating Coronavirus tested the general population in Russia and found a seroprevalence of 14%.,Unclear,,,,No,,,Unclear,,Moscow Times,Cross-sectional survey ,https://www.themoscowtimes.com/2020/06/10/1-in-7-russians-have-coronavirus-immunity-official-a70540 ; https://www.interfax.ru/russia/712617,Kiselyov,rec00f0BqUmdeDfjO,Moderate,kiselyov_1_2020-1,False,Not reported/ Unable to specify,,2020-06-27,2021-06-16,Not enough test information reported to match,True,True,True,,,,,,,,,,,,,,,,,,
2,Validated by independent authors/third party/non-developers,,['Washington'],All,Multiple groups,['IgG'],0.04,2020-04-15,100,Simplified probability,1.0,,201225_Seattle_UniversityofWashington_GenPop_ELISA_RBDIgG,0.87,Serum,ELISA,4.0,2020-03-26,Household and community samples,Local,"Overall, positive on RBD IgG ELISA ",['Spike'],Test Used,King County,2020-12-25,True,Journal Article (Peer-Reviewed),,Unclear,SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing,,,University of Washington,No,Yes,United States of America,No,,Unclear,,Yes,,,,201225_Seattle_UniversityofWashington,,"Researchers at the University of Washington sampled the general population of Seattle, USA, and found a 4% seroprevalence (n=100).",Unclear,,,,No,,,Yes,,The Journal of infectious diseases,Cross-sectional survey ,http://dx.doi.org/10.1093/infdis/jiaa797,Rathe,rec01xH4XCIjJEbG6,High,rathe_sars-cov-2_2021,False,Author designed (ELISA),,2021-06-11,2021-06-16,,,,,30.0,"['Seattle,Washington']",15.0,"Unclear - just says ""Group B subjects were randomly recruited from the community with unknown exposure to or infection with SARS-CoV-2. """,Antibody-positive samples were designated as any samples with an AUC above the mean + 3 SDs of the AUCs of the negative control samples on the ELISA. ,,,,,,,,,,,,,
3,,,['Indiana'],Male,Multiple groups,['IgG'],0.055,2020-05-03,375,Self-referral,0.996,12.0,200513_Indiana_IndianaUniversity_Wave1_NonRandom_Male_PopAdj,1.0,,CLIA,,2020-05-02,Household and community samples,Local,Male,['NR'],Sex/Gender,Marion,2020-07-24,True,Institutional Report,True,Yes,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",,,Indiana University Fairbanks School of Public Health,No,Yes,United States of America,Yes,,Yes,,Yes,,Groups,,200513_Indiana_IndianaUniversity_Wave1_NonRandom,375.0,Indiana University Fairbanks School of Public Health tested 898 individuals in Indiana and found a seroprevalence of 5.8%. ,Unclear,523.0,,,No,,<20 (n=77); 20-39 (n=277); 40-59 (n=369); 60-79 (n=169); >=80 (n=6),No,,Centres for Disease Control,Cross-sectional survey ,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,Menachemi,rec02T2QJbo0Walfr,High,menachemi_population_2020,False,Author designed (ELISA),,2020-08-06,2021-06-19,"Author designed or validated test, not in Finddx database",True,,,,"['Indianapolis,Indiana']",,"Because racial and ethnic minority populations responded at lower rates in the sample, civic leaders were enlisted
to establish 2 days of nonrandom testing (May 2–3) hosted
at Indianapolis locations in two racial/ethnic minority populations. ",,True,Sex: Male ,,,,,,,,,,,
4,Validated by independent authors/third party/non-developers,,['Georgia'],Female,Multiple groups,"['IgG', 'IgA', 'IgM']",0.024,2020-05-03,377,Stratified probability,0.99,0.0,200724_DeKalbFulton_CDCCOVID-19ResponseTeam_Female_PopAdj,0.932,Plasma,,11.0,2020-04-28,Household and community samples,Local,Female,['NR'],Sex/Gender,"DeKalb, Fulton",2020-07-24,True,Journal Article (Peer-Reviewed),True,Yes,"Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.",488,,CDC COVID-19 Response Team,Yes,Yes,United States of America,Yes,Public Health England,Yes,Ortho Clinical Diagnostics - VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total - Total Ig - Serum,Yes,0.85,,,200724_DeKalbFulton_CDCCOVID-19ResponseTeam,317.0,Researchers from the CDC COVID-19 Response Team studied residents in DeKalb and Fulton counties (Atlanta) and found a seroprevalence of 2.5%.,Unclear,377.0,,85,No,0.9940000000000001,,Yes,,MMWR. Morbidity and mortality weekly report,Cross-sectional survey ,https://dx.doi.org/10.15585/mmwr.mm6929e2,Biggs,rec02ukbWxKnIpzy1,Moderate,biggs_estimated_2020,True,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,['Ortho Clinical Diagnostics Inc.'],2020-10-04,2021-06-16,,,,,,,,,,True,Sex: Female,0.051,0.011000000000000001,AND/OR,,,,,,,,
5,Validated by independent authors/third party/non-developers,45.0,,All,Multiple groups,['IgG'],0.44,2020-08-20,84,Stratified non-probability,1.0,36.0,210408_Malegaon_MunicipalCorporationofMalegaon_36-45,0.93,,ELISA,37.0,2020-07-25,Household and community samples,Local,age 36-45,['NR'],Age,,2021-04-08,True,Journal Article (Peer-Reviewed),,,"Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra.",,,The Municipality of Malegaon ,,,India,,,,,,,Groups,,210408_Malegaon_MunicipalCorporationofMalegaon,175.0,The Municipality of Malegaon studied a community-based sample (n=336) and found a seroprevalence rate of 40%. ,,161.0,,,,,"15-25 (n=64), 26-35 (n=107), 36-45 (n=84), 46-60 (n=69), 61-70 (n=12)",,,Journal of family medicine and primary care,Cross-sectional survey ,https://dx.doi.org/10.4103/jfmpc.jfmpc_2191_20,Saple,rec033psJDYhhvZzk,Moderate,sapleSeroprevalenceAntiSARSCoV2IgG2021,True,Not reported/ Unable to specify,,2021-06-06,2021-06-17,,,True,True,,['Malegaon'],,"The community-based cross sectional study was conducted in total 98 closed containment zones demarcated by Municipal Corporation, Malegaon. The study was conducted from 25 July to 20 Aug 2020. Approval of the Shri Bhausaheb Hire Government Medical College, (SBHGMC, Dhule) Institutional Ethics committee (IEC) was obtained prior to commencement of the study. Written informed consent was obtained prior to data collection, Data collection tools were prepared with the help of WHO community-based serosurvey for anti-SARS-CoV-2 IgG antibody detection in community.",,,,,,,,,,,,,,
6,,,['Florida'],All,Adults (18-64 years),"['IgG', 'IgM']",0.009000000000000001,2020-10-19,3648,Convenience,,,210422_Orlando_JohnsHopkinsUniversity,,Serum,Multiple Types,33.0,2020-06-11,Non-essential workers and unemployed persons,Local,Overall NBA bubble,"['Spike', 'Nucleocapsid (N-protein)']",Primary Estimate,Orange County,2021-04-22,True,Journal Article (Peer-Reviewed),,,"SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.",,,Johns Hopkins University School of Medicine,,,United States of America,,,,,,,Groups,,210422_Orlando_JohnsHopkinsUniversity,2915.0,"Researchers at Johns Hopkins University School of Medicine studied members of the National Basketball Association ""NBA Bubble"" in Orlando, Florida, and found a seroprevalence of 0.9% (n=3648)",,,,,,,"<30 (n=956), >30 (n=2692)",,,JAMA internal medicine,Cross-sectional survey ,https://dx.doi.org/10.1001/jamainternmed.2021.2114,Mack,rec03UxQ6CfirRvlX,Moderate,mack_sars-cov-2_2021,False,"Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Elecsys® Anti‐SARS‐CoV‐2","['Siemens', 'Abbott Laboratories', 'Ortho Clinical Diagnostics Inc.', 'Roche Diagnostics', ' Basel', ' Switzerland']",2021-05-19,2021-06-16,,,True,True,,"['Orlando,Florida']",,"Members of the National Basketball Association ""NBA Bubble"" workers and players",Positive on one of the assays. ,,,,,AND/OR,,,,,,,,
7,Validated by independent authors/third party/non-developers,39.0,['Missouri'],All,Adults (18-64 years),['IgG'],0.0244,2020-05-12,1,Sequential,0.9870000000000001,30.0,210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults_30-39_unadj,0.9820000000000001,Multiple Types,ELISA,,2020-04-27,Residual sera,Local,"30-39
","['Spike', 'Nucleocapsid (N-protein)']",Age,,2021-02-03,True,Journal Article (Peer-Reviewed),,No,"Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA",,,Washington University School of Medicine,No,Yes,United States of America,Yes,,Unclear,,Yes,,Median,18-93,210203_StLouis_WashingtonUniversitySchoolofMedicine_Adults,207.0,"Washington University School of Medicine studied children and adults in St. Louis, Missouri and found a seroprevalence of 1.71% in children and 3.11% in adults.",N/A,296.0,,,No,,61,No,Total Range,mSphere,Cross-sectional survey ,https://dx.doi.org/10.1128/mSphere.01207-20,Smith,rec03bRAlr7AwO0Pd,High,smith_seroprevalence_2021,True,Author designed (ELISA),,2021-03-13,2021-06-16,"Author designed or validated test, not in Finddx database",,,,41.0,"['St Louis,Missouri']",,the adult sam- ples were residual samples sent to Barnes-Jewish Hospital for physician-ordered vitamin D testing between 27 April 2020 and 12 May 2020.,,,,,,,,,,,,,,
8,,,['South-Kivu'],All,Adults (18-64 years),['IgG'],0.41200000000000003,2020-08-19,359,Convenience,0.986,,210216_Bukavu_UniversitéLibredeBruxelles_OverallELISA,0.617,,ELISA,148.0,2020-07-02,Health care workers and caregivers,Local,,['NR'],Primary Estimate,,2021-02-16,True,Journal Article (Peer-Reviewed),,No,"High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo",145,10.1093/clinchem/hvaa120,Université Libre de Bruxelles (ULB),No,Yes,Democratic Republic of the Congo,Yes,Barnes Jewish Hospital Laboratory,Unclear,EUROIMMUN AG - EI SARS-Cov-2 IgG assay - IgG - Serum,No,0.621,Mean,11.3,210216_Bukavu_UniversitéLibredeBruxelles,182.0,"Université Libre de Bruxelles studied healthcare workers in Bukavu, Eastern Democratic Republic of Congo and found a seroprevalence of 41.2%.",Yes,177.0,,64,No,0.948,43.1,No,SD - standard deviation,The American journal of tropical medicine and hygiene,Cross-sectional survey ,https://dx.doi.org/10.4269/ajtmh.20-1526,Mukwege,rec045e4kev4pC39P,High,mukwege_high_2021,False,"Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)",['EUROIMMUN AG'],2021-03-14,2021-06-16,,,True,True,,"['Bukavu,South-Kivu']",,,,,Healthcare worker,,,,,,,,,,,
9,,,['Quebec'],All,Adults (18-64 years),['IgG'],0.12,2020-07-27,99,Convenience,0.97,,201027_Montreal_ShrinersHospital_employees_unadj,,Serum,ELISA,12.0,2020-06-10,Health care workers and caregivers,Local,Hospital employees,['NR'],Population,,2020-10-27,True,Journal Article (Peer-Reviewed),True,Yes,Prevalence of SARS-CoV-2 Infections in a Pediatric Orthopedic Hospital,549,10.1101/2020.04.29.20082099,Shriners Hospital for Children,No,Yes,Canada,Yes,"Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine",No,Mologic Ltd - SARS-CoV-2 ELISA Serology - IgG - Serum,Unclear,0.8809999999999999,Median,"Patients 13.4-16.8, accompanying persons 41.4- 50.8, employees 32.5-52.5",201027_Montreal_ShrinersHospital,60.0,"McGill University studied children, accompanying persons, and employees of a hospital (n=199) and found a seroprevalence of  11%",Unclear,139.0,,238,No,0.973,"Patients: 15.6, Accompanying persons: 47.1, Employees 42.5 ",No,IQR - interquartile range,Pediatric anesthesia,Cross-sectional survey ,https://doi.org/10.1111/pan.14047,Bardai,rec05EuYXXZTFP3jv,High,bardai_prevalence_2021,False,"COVID-19 IgG ELISA,SARS-CoV-2 ELISA Serology","['Omega diagnostics', 'Mologic']",2020-12-18,2021-06-16,,,,,,"['Montreal,Quebec']",,,,,,,,,,,,,,,,
10,Validated by independent authors/third party/non-developers,,['California'],All,Adults (18-64 years),['IgG'],0.0041322314,2020-05-20,242,Convenience,0.9975,,201209_SantaClara_StanfordHealthCare_other,0.87,Serum,CLIA,1.0,2020-04-20,Health care workers and caregivers,Local,Other,['Spike'],Race,Santa Clara County,2020-12-09,True,Journal Article (Peer-Reviewed),True,Yes,Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic.,,,Stanford Health Care,Yes,Yes,United States of America,Yes,,Yes,,No,,Mean,11.6,201209_SantaClara_StanfordHealthCare,2914.0,"Researchers at Stanford Health Care, Santa Clara county USA,  tested 10,449 health care personnel in their hospital system and found 1.3% seroprevalence. ",Unclear,6790.0,,,No,,40.9,No,SD - standard deviation,Infection control and hospital epidemiology,Cross-sectional survey ,https://dx.doi.org/10.1017/ice.2020.1358,Rosser,rec062y4Vy7XsISrr,High,rosser_severe_2020,False,Author designed (ELISA),,2021-03-11,2021-06-16,"Author designed or validated test, not in Finddx database",True,,,397.0,"['San Francisco Bay Area,California']",,All employees of Stanford Health Care. Assumed adults due to working HCW population. ,Positive IgG RBD result ,,Race: Multiple/Other,,,,,,,,,,,
11,Validated by developers/manufacturers,,['Grand Est'],All,Multiple groups,['IgG'],0.076,2020-06-02,1191,Stratified probability,1.0,15.0,210115_France_InstitutNationaldelaStatistiqueetdesÉtudesÉconomiques_Bas-Rhin,0.9440000000000001,Dried Blood,ELISA,86.0,2020-05-02,Household and community samples,Local,Bas-Rhin,['Spike'],Geographical area,Bas-Rhin,2021-01-15,True,Institutional Report,,Yes,"In May 2020, 4.5% of the population of metropolitan France had developed antibodies against SARS-CoV-2",145,10.1093/clinchem/hvaa120,l’Institut national de la santé et de la recherche médicale (Inserm) ,Yes,Yes,France,Yes,Barnes Jewish Hospital Laboratory,Yes,EUROIMMUN AG - EI SARS-Cov-2 IgG assay - IgG - Serum,Yes,0.621,Groups,,210115_France_InstitutNationalDeLaSantéEtDeLaRechercheMédicale,5469.0,"Researchers at the l’Institut national de la santé et de la recherche médicale (Inserm) tested 12,114 members of the general population of France and found a 4.5% seroprevalence. ",No,6645.0,,64,No,0.948,"15-20 (n = 928)
21-29 (n = 1253) 
30-49 (n = 4072) 
50-64 (n = 3375) 
> 64 (n = 2486)
",Yes,,"Direction de la recherche, des études, de l'évaluation et des statistiques",Prospective cohort,https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-01/er1167-en.pdf,Warszawski,rec069UlVq7uEpHgo,Low,josiane_warszawski_may_2021,True,"Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)",['EUROIMMUN AG'],2021-03-11,2021-06-16,,,,,,,,French general population,,True,,0.096,0.057,,,,,,,,,
12,Validated by independent authors/third party/non-developers,,['Limburg'],All,Adults (18-64 years),"['IgG', 'IgM']",0.11111111111111101,2020-04-16,9,Convenience,0.951,,201018_Belgium_UniversityHospitalsLeuven_OtherProfession_unadj,0.747,Whole Blood,LFIA,1.0,2020-04-14,Health care workers and caregivers,Local,Other staff,['NR'],Type of health care worker,,2020-10-18,True,Journal Article (Peer-Reviewed),True,Yes,Added value of anti-SARS-CoV-2 antibody testing in a Flemish nursing home during an acute COVID-19 outbreak in April 2020,,,University of Leuven,No,Yes,Belgium,No,,No,,No,,Mean,,201018_Belgium_UniversityHospitalsLeuven,,Researchers from University Hospitals Leuven studied residents and staff of a Flemish nursing home in Belgium and found a seroprevalence of 17% in residents and 20% in staff (n=188).,Yes,188.0,,,No,,86,No,,Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine,Cross-sectional survey ,http://dx.doi.org/10.1080/17843286.2020.1834285,Buntinx,rec07CPYVxiOxxOgX,High,buntinx_added_2020,False,COVID-19 antibody rapid test,['SureScreen Diagnostics'],2021-01-16,2021-06-16,"Evaluations for separate isotypes, review authors report combined positivity rate (and/or isotype)",True,,,103.0,"['Lanaken,Limburg']",186.0,Mixed staff and residents in a nursing home,Positive for IgM and/or IgG,,,,,AND/OR,,,,,,,,
13,Validated by developers/manufacturers,69.0,['Rio de Janeiro'],All,Adults (18-64 years),"['IgG', 'IgM']",0.033,2020-04-27,2857,Sequential,0.99,18.0,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro_BloodDonors_OverallAdj,0.85,Serum,LFIA,103.0,2020-04-14,Blood donors,Local,"Adjusted: population, test",['Not reported'],Primary Estimate,,2020-07-06,True,Journal Article (Peer-Reviewed),True,No,"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil",,,Universidade do Estado do Rio de Janeiro,Yes,Yes,Brazil,Yes,,Unclear,,No,,Groups,,200706_RiodeJaneiro_UniversidadedoEstadodoRiodeJaneiro,1450.0,Federal University of Rio de Janeiro studied blood donors in April and found a seroprevalence of 4% (n=2857).,Yes,1407.0,,,Yes,,18-29 (n=870); 30-49 (n=1443); 50-69 (n=544),No,,Revista de Saude Publica,Cross-sectional survey ,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334006/,Filho,rec07Gscq4Z51xHfc,Moderate,filho_seroprevalence_nodate,True,MedTest Coronavirus 2019-nCoV IgG/IgM,['MedLevensohn'],2020-07-10,2021-06-16,Commercially available but not in the Finddx database ,True,True,,,"['Rio de Janeiro,Rio de Janeiro']",,,Calculated number (adjusted) of individuals who test positive for Abs against sars-cov-2,True,,0.040999999999999995,0.026000000000000002,AND/OR,True,,,,,,,
14,Validated by independent authors/third party/non-developers,,['Sao Paulo State'],All,Multiple groups,['IgG'],0.131,2020-06-20,880,Sequential,0.961,,210115_SaoPaulo_UniversidadedeSãoPaulo_Jun_PopTestAdj,0.922,Serum,CLIA,135.0,2020-06-08,Blood donors,Local,Pop/test adj,['Nucleocapsid (N-protein)'],Primary Estimate,,2021-01-16,True,Journal Article (Peer-Reviewed),True,No,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic,163,,Universidade de Sao Paulo,Yes,Yes,Brazil,No,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,,,210115_SaoPaulo_UniversidadedeSãoPaulo_Jun,,"Researchers at the Universidade de São Paulo studied blood donors in Sao Paulo, Brazil, and found a seroprevalence of 13.1% in June (n=880)",N/A,,,73,Yes,1.0,,No,,Science,Cross-sectional survey ,https://science.sciencemag.org/content/371/6526/288,Buss,rec086NJrHaGouXuk,Moderate,buss_three-quarters_2021,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2021-04-07,2021-06-19,,,True,,821.0,"['Sao Paulo,Sao Paulo State']",193.0,"Blood donors in Sao Paulo; specific age frame NR, but likely spans many age groups",0.4 S/co cutoff,True,,0.163,0.10300000000000001,,True,,,,,,,
15,Validated by developers/manufacturers,,['Honshu'],All,Adults (18-64 years),"['IgM', 'IgG']",0.0,2020-05-29,1000,Convenience,0.998,,210226_Iwate_IwatePrefecturalCentralHospital_HCW_Roche,1.0,Serum,CLIA,0.0,2020-05-18,Health care workers and caregivers,Local,Roche Elecsys® Anti- SARS- CoV- 2 RUO Assay,['NR'],Test Used,Iwate,2021-02-26,True,Journal Article (Peer-Reviewed),True,Yes,"Orthogonal antibody testing for COVID-19 among healthcare workers in a non-epidemic place and time:Japan's Iwate Prefecture, May 18-31, 2020",472,,Iwate Prefectural Central Hospital,Yes,Yes,Japan,Yes,Diagnostic Support Group (DSP) at PHE Porton,Unclear,Roche - Elecsys Anti‐SARS‐CoV‐2 - IgG; IgM - Serum,Yes,0.8390000000000001,Mean,11,210226_Iwate_IwatePrefecturalCentralHospital,264.0,"Iwate Prefectura Central Hospital studied health care workers (n=1000) in Morioka, Japan and found a seroprevalence of 0%.",N/A,736.0,,78,No,1.0,40,Unclear,SD - standard deviation,Fukushima Journal of Medical Science,Cross-sectional survey ,https://dx.doi.org/10.5387/fms.2020-21,Nakamura,rec08CiDR3GIRGRWv,High,nakamura_orthogonal_2020,False,Elecsys® Anti‐SARS‐CoV‐2,"['Roche Diagnostics', ' Basel', ' Switzerland']",2020-06-19,2021-06-16,,,,,,"['Morioka,Honshu']",,"Healthcare workers (physicians, nurses, pharmacists, radiographers, laboratory technicians, and medical office workers) at Iwate Prefectural Central Hospital",Positive for IgM and IgG antibodies on Roche assay,,,,,AND,,,,,,,,
16,Multiple tests with diff validations or values derived from each type,,,Female,Multiple groups,"['IgG', 'Total Antibody']",0.016390000000000002,2020-03-16,122,Sequential,,,210201_France_TissueBankofLille_female_unadj,,Serum,Multiple Types,2.0,2019-11-01,Tissue donor,Local,Female,"['Nucleocapsid (N-protein)', 'Spike']",Sex/Gender,,2021-02-01,True,Journal Article (Peer-Reviewed),True,No,Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France,,,CHU Lille,No,Yes,France,Yes,,Yes,,Yes,,Median,57-79,210201_France_TissueBankofLille,113.0,"CHU Lille studied tissue donors in Lille, France and found a seroprevalence of 1.7%.",N/A,122.0,,,No,,68yo,No,IQR - interquartile range,Cell and tissue banking,Cross-sectional survey ,https://dx.doi.org/10.1007/s10561-021-09901-3,Germain,rec08T3JqHDL86tDc,High,germain_retrospective_2021,False,"Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","['Abbott Laboratories', 'Beijing Wantai Biological']",2021-03-13,2021-06-16,Multiple tests used,True,,,,['Lille'],,Tissue donors; not necessarily seeking healthcare and not all donors are living. Difficult to find a suitable sample frame.,Abott Architect IgG positivity threshold >= 1.4  and Wantai total antibodies positivity threshold >= 1.1,,Sex: Female,,,AND/OR,,,,,,,,
17,Multiple tests with diff validations or values derived from each type,60.0,,All,Adults (18-64 years),"['IgG', 'Total Antibody', 'IgM']",0.0222,2020-04-15,17794,Convenience,,18.0,210302_Wuhan_ChineseAcademyofMedicalSciences1_overall_unadj,,,Neutralization,395.0,2020-01-15,Blood donors,Local,,['Spike'],Analysis,,2021-03-02,True,Journal Article (Peer-Reviewed),,,The prevalence of antibodies to SARS-CoV-2 among blood donors in China,,,Chinese Academy of Medical Sciences,,,China,,,,,,,Median,19-47,210302_Wuhan_ChineseAcademyofMedicalSciences1,11077.0,Chinese Academy of Medical Sciences studied blood donors in Wuhan (n=17794) and found a seroprevalence of 2.66%.,,6717.0,,,,,33,,IQR - interquartile range,Nature communications,Cross-sectional survey ,https://dx.doi.org/10.1038/s41467-021-21503-x,Chang,rec08Yq6frX7sOOIE,Moderate,le_chang_prevalence_2020,True,Neutralizing assay,,2021-04-12,2021-06-16,,,,True,,['Wuhan'],,,,,,0.0245,0.0201,AND/OR,,,,,,,,
18,Validated by independent authors/third party/non-developers,69.0,['Lombardy'],All,Adults (18-64 years),['IgM'],0.139,2020-04-16,158,Convenience,0.9059999999999999,20.0,200729_Milan_UniversitadegliStudidiMilano_Contact_IgM,0.887,Serum,LFIA,22.0,2020-04-02,Health care workers and caregivers,Local,Contact with COVID-19 patients,['Spike'],Health care worker exposure,,2020-07-29,True,Journal Article (Peer-Reviewed),True,Yes,SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital,94,,Università degli Studi di Milano ,No,Yes,Italy,Yes,University of California,Yes,"BioMedomics, Inc. - COVID-19 IgM-IgG Dual Antibody Rapid Test - IgM - Plasma; Serum",No,0.617,Groups,35-54,200729_Milan_UniversitadegliStudidiMilano,70.0,"Università degli Studi di Milano studied 202 health care workers in Milan,Italy and found a seroprevalence of 7.4%.",Unclear,132.0,,79,No,0.879,20-29 (n=27); 30-39 (n=44); 40-49 (n=57); 50-59 (n=51); 60-69 (n=23),No,IQR - interquartile range,BMC PULMONARY MEDICINE,Cross-sectional survey ,https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01237-0,Sotgiu,rec08rGr4Ml4VLc1N,High,sotgiu_sars-cov-2_2020,False,COVID-19 IgM-IgG Dual Antibody Rapid Test,"['BioMedomics', ' Inc.']",2020-09-29,2021-06-16,,,,,,"['Milan,Lombardy']",,"A total of 5.7 mL of blood samples were collected from
202 apparently healthy workers of San Paolo University
General Hospital.",,,HCW Exposure: Contact with COVID-19 patients,0.267,0.085,,,,,,,,,
19,,,,All,Multiple groups,['IgG'],0.03,2020-06-15,404,Sequential,,,210212_Oxford_UniversityofOxford,,Serum,,12.0,2020-04-15,Patients seeking care for non-COVID-19 reasons,Local,,['NR'],Primary Estimate,,2021-02-12,True,Journal Article (Peer-Reviewed),,No,Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic,163,,University of Oxford,No,Yes,The United Kingdom,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Unclear,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Unclear,0.41200000000000003,Median,29.0-60.0,210212_Oxford_UniversityofOxford,214.0,University of Oxford studied sera from 404 patients attending  John Radcliffe Hospital for maintenance infliximab or vedolizumab infusions and reported an overall seroprevalence of 3.0%.,N/A,190.0,,73,No,1.0,44,No,IQR - interquartile range,Gut,Cross-sectional survey ,https://dx.doi.org/10.1136/gutjnl-2021-324116,McGregor,rec08uycrKqDicMqY,High,mcgregor_maintenance_2021,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2021-03-27,2021-06-16,,,True,True,,['Oxford'],,Sera from patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at the John Radcliffe Hospital,,,,,,,,,,,,,,
20,Validated by developers/manufacturers,39.0,,All,Multiple groups,['IgG'],0.109,2020-06-23,2262,Simplified probability,0.9770000000000001,,200918_France_ParisUniversity_<40PopAdj,0.9790000000000001,Dried Blood,ELISA,245.0,2020-05-04,Household and community samples,National,<40 ,['Spike'],Age,,2020-09-18,True,Preprint,True,Yes,Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study,145,10.1093/clinchem/hvaa120,Paris University,Yes,Yes,France,Yes,Barnes Jewish Hospital Laboratory,Unclear,EUROIMMUN AG - EI SARS-Cov-2 IgG assay - IgG - Serum,Yes,0.621,Groups,,200918_France_ParisUniversity,5809.0,"Researchers from Paris University sampled 14,628 participants in the adult general population of France and found a 6.72% seroprevalence. ",No,8818.0,,64,No,0.948,"<40 (n=2262), 40-50 (n=2897), 50-60 (n=3019), 60-70 (3272), 70+ (n=3175)",Yes,,medRxiv,Prospective cohort,https://www.medrxiv.org/content/10.1101/2020.09.16.20195693v1,Carrat,rec08zZcF3RObYoDj,Moderate,carrat_seroprevalence_2020,True,"Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)",['EUROIMMUN AG'],2021-01-13,2021-06-16,,,,,,,,General population sample of adults and seniors,a test was considered to be ELISA-positive with an optical density ratio ≥ 1.1,True,,0.12400000000000001,0.092,,,,,,,,,
21,Validated by independent authors/third party/non-developers,,['Capital Region of Denmark'],All,Adults (18-64 years),['IgG'],0.0267,2020-04-22,5809,Entire sample,0.997,,200803_CapitalRegionDenmark_UniversityofCopenhagen_hcw_PatientContactPartTime_IgG,0.794,Whole Blood,LFIA,155.0,2020-04-15,Health care workers and caregivers,Regional,Patient Contact Part Time ,['NR'],Exposure level granular,,2020-08-03,True,Journal Article (Peer-Reviewed),True,Yes,Risk of COVID-19 in health-care workers in Denmark: an observational cohort study,100,10.1128/jcm.00461-20,University of Copenhagen,Yes,Yes,Denmark,Yes,General Hospital of the Central Theater Command of the People’s Liberation Army (PLA),Yes,Zhuhai Livzon Diagnostics Inc - 2019-nCoV IgG/IgM Antibody Detection Kit - IgG - Serum,No,0.701,Mean,12.6,200803_CapitalRegionDenmark_UniversityofCopenhagen_1_HCW,6077.0,University of Copenhagen studied health-care workers (n=29295) in the Capital Region of Denmark and found a 4% seroprevalence. ,Yes,22715.0,,150,Yes,1.0,44.4,Yes,SD - standard deviation,The Lancet. Infectious diseases,Cross-sectional survey ,https://dx.doi.org/10.1016/S1473-3099(20)30589-2,Iversen,rec09H5Aj3t8OzPSN,Low,iversen_risk_2020,False,2019-nCoV IgG/IgM Antibody Detection Kit,['Zhuhai Livzon Diagnostics Inc'],2020-10-05,2021-06-16,,,,,651.0,,155.0,,"The test results were read after 15 min. When no control line appeared or if the reading chamber was discoloured by blood the test was repeated. Test results were binary and read by the individual participant, assisted by local staff if needed. Instructions on how to read the results were posted online, in a video instruction, and sent by email to all participants. Inconclusive test results were treated as negative unless otherwise stated. ",,,,,,,,,,,,,
22,Validated by developers/manufacturers,,['New York'],All,Adults (18-64 years),['IgG'],0.25,2020-05-01,361,Convenience,0.9959999999999996,20.0,201015_NewYorkCity_NYCHealth+Hospitals/Lincoln_N95andSurgicalMask,1.0,Serum,CLIA,90.0,2020-03-01,Health care workers and caregivers,Local,PPE: Surgical mask and PPE,['Nucleocapsid (N-protein)'],Exposure level granular,"New York, Kings, Queens, Bronx, Richmond",2020-10-15,True,Journal Article (Peer-Reviewed),True,Yes,SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic,163,,NYC Health + Hospitals/Lincoln,No,Yes,United States of America,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Groups,,201015_NewYorkCity_NYC Health+Hospitals/Lincoln,149.0,Researchers at the NYC Health + Hospitals/Lincoln tested 500 health care workers at a hospital in New York City and found a 27% seroprevalence.,Yes,329.0,,73,No,1.0,"20-39 (n=230), 40-59 (n=196), 60+ (n=52)",No,,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,Cross-sectional survey ,http://dx.doi.org/10.1016/j.ijid.2020.10.036,Venugopal,rec09Knh4bDpjMiw9,Moderate,venugopal_sars-cov-2_2020,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2020-12-19,2021-06-16,,,,,,"['New York City,New York']",,Health care workers at heavily impacted NYC hospital,,,,,,,,,,,,,,
23,Validated by independent authors/third party/non-developers,19.0,['California'],All,Children and Youth (0-17 years),['IgG'],0.111,2020-07-27,9,Sequential,1.0,10.0,201123_OrangeCounty_StJudeMedicalCenter_10-19,1.0,Serum,,1.0,2020-07-15,Residual sera,Local,10-19,['NR'],Age,Orange County,2020-11-23,True,Journal Article (Peer-Reviewed),True,No,"Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California",163,,St. Jude Medical Center,Yes,Yes,United States of America,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Unclear,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Groups,,201123_OrangeCounty_StJudeMedicalCenter,387.0,"Researchers at St. Jude Medical Center in Orange County, USA, tested 865 outpatients and found a 9.4% seroprevalence. ",Unclear,478.0,,73,No,1.0,"10-19 (N=9), 20-29 (n=55), 30-39 (n=81), 40-49 (n=83), 50-59 (n=133), 60-69 (n=159), 70-79 (n=164), 80-89 (n=144), 90-99 (n=35), 100-109 (n=2)",No,,Journal of racial and ethnic health disparities,Cross-sectional survey ,https://dx.doi.org/10.1007/s40615-020-00918-0,Yamaki,rec09O3AZzPh9IAfE,High,yamaki_seroprevalence_2020,True,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2021-01-21,2021-06-16,,,,,,"['Fullerton,California']",,Emergency department patients and outpatients,,,,0.457,0.0001,,,,,,,,,
24,,,['North Dakota'],All,Multiple groups,"['IgA', 'IgG', 'IgM', 'Total Antibody']",0.011899999999999999,2020-07-31,14499,Sequential,,16.0,200918_UnitedStates_Vitalant_Fargo,,Serum,CLIA,173.0,2020-06-01,Blood donors,Local,"Fargo, ND",['Spike'],Geographical area,,2020-09-18,True,Preprint,True,No,Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors,488,,Vitalant,Yes,Yes,United States of America,Yes,Public Health England,Unclear,Ortho Clinical Diagnostics - VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total - Total Ig - Serum,Unclear,0.85,Groups,,200918_UnitedStates_Vitalant,90131.0,"A large blood center began testing for antibodies against SARS-CoV-2 across the US, and a seroprevalence of 1.83% among the 252882 blood donors was reported. ",N/A,99525.0,,85,No,0.9940000000000001,16-17 (n=1812); 18-29 (n=22048); 30-39 (n=30956); 40-49 (n=34151); 50-64 (n=66030); 65-74 (n=28453); 75-84 (n=5848); >85 (n=357),Yes,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1.full.pdf,Vassallo,rec0AHWu48CrEX0Hr,Moderate,vassallo_seroprevalence_2020,False,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,['Ortho Clinical Diagnostics Inc.'],2020-10-14,2021-06-16,,,,,,"['Fargo,North Dakota']",,,Unique individuals who test positive for SARS-CoV-2,,,,,AND/OR,,,,,,,,
25,Multiple tests with diff validations or values derived from each type,65.0,['Ohio'],All,Adults (18-64 years),"['IgG', 'IgM']",0.0,2020-05-19,12,Convenience,,22.0,201030_Cleveland_CaseWesternReserveUniversity_WhiteHispanic,,Serum,ELISA,0.0,2020-04-20,Essential non-healthcare workers,Local,White Hispanic,['NR'],Ethnicity,Cuyahoga,2020-10-30,True,Journal Article (Peer-Reviewed),True,Yes,SARS-CoV-2 Infection Among Serially Tested Emergency Medical Services Workers,97,,Case Western Reserve University,No,Yes,United States of America,Yes,University of California,Yes,"Epitope Diagnostics, Inc. - EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit; EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit - IgG; IgM - Plasma; Serum",Unclear,0.754,Mean,,201030_Cleveland_CaseWesternReserveUniversity,253.0,"Researchers at the Case Western Reserve University serosurveyed 296 first responders in Cleveland, USA, and found a 5.4% seroprevalence. ",Yes,42.0,,98,No,0.898,44.1,No,,Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors,Cross-sectional survey ,https://dx.doi.org/10.1080/10903127.2020.1831668,Tarabichi,rec0BInNunRIymvBy,High,tarabichi_sars-cov-2_2020,False,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit","['Epitope Diagnostics', ' Inc.']",2020-12-21,2021-06-16,,,,,,"['Cleveland,Ohio']",,First responders: EMS and Fire Dept,Positive testing was regarded as any positive SARS-CoV-2 PCR (at the revised threshold) or non-equivocally positive serological assay,,Ethnicity: Hispanic,,,AND/OR,,,,,,,,
26,,,['Hubei'],All,Adults (18-64 years),['IgM'],0.0059,2020-03-25,505,Convenience,,18.0,200901_Wuhan_ZhongnanHospitalofWuhanUniversity_IgM_Admin,,Serum,CLIA,3.0,2020-03-16,Health care workers and caregivers,Local,"Administrative healthcare worker, IgM+/IgG-","['Spike', 'Nucleocapsid (N-protein)']",Type of health care worker,,2020-09-14,True,Journal Article (Peer-Reviewed),True,Yes,Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff:a cross-sectional survey,399,10.1101/2020.05.05.20092551.t,Zhongnan Hospital of Wuhan University,Yes,Yes,China,Yes,"Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA",Yes,Shenzhen Yahuilong Biotechnology Co Ltd - 2019-nCoV IgG/IgM Antibody Detection Kit - IgM - Serum,Unclear,0.33299999999999996,Groups,,200901_Wuhan_ZhongnanHospitalofWuhanUniversity,1188.0,"Researchers at the Zhongnan Hospital of Wuhan University, China, tested 3674 hospital staff and found 1.6% had IgG seropositivity and an additional 0.74% with IgM/nucleic acid seropositivity. ",Yes,2486.0,,4,No,0.998,18-30 (n=1378); 31-50 (n=1656); >50 (n=640),No,,EClinicalMedicine,Cross-sectional survey ,http://dx.doi.org/10.1016/j.eclinm.2020.100510,Zhou,rec0BJW9DoanUowKH,Moderate,zhou_tracing_2020,False,iFlash-SARS-CoV-2 IgM/IgG,['Shenzhen Yhlo Biotech Co. Ltd'],2020-10-29,2021-06-16,,,,,,"['Wuhan,Hubei']",, Asymptomatic hospital staff at Zhongnan Hospital of Wuhan University,IgM positive,,,,,,,,,,,,,
27,Validated by developers/manufacturers,,,All,Multiple groups,['Total Antibody'],0.08900000000000001,2020-06-15,9737,Stratified probability,0.998,18.0,200925_UnitedStates_StanfordUniversity_ZCTAIntegratedPopAdj,1.0,,CLIA,713.0,2020-06-15,Residual sera,National,Integrated ethnicity adjusted to US general population,['Spike'],Ethnicity,,2020-09-25,True,Journal Article (Peer-Reviewed),True,No,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,499,,Stanford University,Yes,Yes,United States of America,Yes,,Yes,Siemens - Atellica® IM SARS-CoV-2 Total (COV2T) - Total Ig - Serum,Yes,0.86,Groups,,200925_UnitedStates_StanfordUniversity,16348.0,Researchers at Stanford University tested dialysis samples from across the USA and found a 9·3% (adjusted) seroprevalence. ,Yes,12155.0,,86,Yes,1.0,18-44 (n=3303); 45-64 (n=11541); 65-79 (n=10220); 80+ (n=3439),Yes,,The Lancet,Cross-sectional survey ,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,Anand,rec0BdPT6Q27SmUe0,Moderate,anand_prevalence_2020,True,ADVIA Centaur Immunoassay System,['Siemens'],2020-11-22,2021-06-16,,,,,,,,"We did a cross-sectional analysis of adult (≥18 years) patients undergoing monthly laboratory testing at Ascend Clinical using samples obtained for routine clinical care that otherwise would have been discarded. Ascend Clinical is a commercial clinical laboratory based in Redwood City, California, that receives samples from a nationwide network of around 1300 dialysis facilities, serving approximately 65 000 patients",,True,Ethnicity: Other,0.098,0.08,,,,,,,,,
28,Validated by developers/manufacturers,,,All,Multiple groups,['Total Antibody'],0.099,2020-06-15,4894,Stratified probability,0.998,18.0,200925_UnitedStates_StanfordUniversity_BlackPopAdj,1.0,,CLIA,467.0,2020-06-15,Residual sera,National,Black adjusted to US general population,['Spike'],Race,,2020-09-25,True,Journal Article (Peer-Reviewed),True,No,Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,499,,Stanford University,Yes,Yes,United States of America,Yes,,Yes,Siemens - Atellica® IM SARS-CoV-2 Total (COV2T) - Total Ig - Serum,Yes,0.86,Groups,,200925_UnitedStates_StanfordUniversity,16348.0,Researchers at Stanford University tested dialysis samples from across the USA and found a 9·3% (adjusted) seroprevalence. ,Yes,12155.0,,86,Yes,1.0,18-44 (n=3303); 45-64 (n=11541); 65-79 (n=10220); 80+ (n=3439),Yes,,The Lancet,Cross-sectional survey ,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext,Anand,rec0BeeJzvlhWbwjU,Moderate,anand_prevalence_2020,True,ADVIA Centaur Immunoassay System,['Siemens'],2020-11-22,2021-06-16,,,,,,,,"We did a cross-sectional analysis of adult (≥18 years) patients undergoing monthly laboratory testing at Ascend Clinical using samples obtained for routine clinical care that otherwise would have been discarded. Ascend Clinical is a commercial clinical laboratory based in Redwood City, California, that receives samples from a nationwide network of around 1300 dialysis facilities, serving approximately 65 000 patients",,True,Race: Black,0.113,0.087,,,,,,,,,
29,,,['Indiana'],All,Seniors (65+ years),['IgG'],0.168,2020-05-03,6,Self-referral,0.996,80.0,200513_Indiana_IndianaUniversity_Wave1_NonRandom_Age>=80_PopAdj,1.0,,CLIA,,2020-05-02,Household and community samples,Local,>=80,['NR'],Age,Marion,2020-07-24,True,Institutional Report,True,Yes,"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020",,,Indiana University Fairbanks School of Public Health,No,Yes,United States of America,Yes,,Yes,,Yes,,Groups,,200513_Indiana_IndianaUniversity_Wave1_NonRandom,375.0,Indiana University Fairbanks School of Public Health tested 898 individuals in Indiana and found a seroprevalence of 5.8%. ,Unclear,523.0,,,No,,<20 (n=77); 20-39 (n=277); 40-59 (n=369); 60-79 (n=169); >=80 (n=6),No,,Centres for Disease Control,Cross-sectional survey ,https://www.cdc.gov/mmwr/volumes/69/wr/mm6929e1.htm?s_cid=mm6929e1_w,Menachemi,rec0BgJvT6IpuDWtl,High,menachemi_population_2020,False,Author designed (ELISA),,2020-08-06,2021-06-16,"Author designed or validated test, not in Finddx database",True,,,,"['Indianapolis,Indiana']",,"Because racial and ethnic minority populations responded at lower rates in the sample, civic leaders were enlisted
to establish 2 days of nonrandom testing (May 2–3) hosted
at Indianapolis locations in two racial/ethnic minority populations. ",,True,,,,,,,,,,,,
30,Validated by independent authors/third party/non-developers,,['Abruzzo'],Male,Multiple groups,['Total Antibody'],0.111,2020-04-19,352,Entire sample,1.0,0.0,201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseG.Caporale_Male,0.93,Serum,ELISA,,2020-04-18,Household and community samples,Local,Male,['Spike'],Sex/Gender,Chieti,2020-10-31,True,Journal Article (Peer-Reviewed),True,Yes,A COVID-19 Hotspot Area: Activities and Epidemiological Findings.,231,10.1016/j.jviromet.2020.113919,Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale ,Yes,Yes,Italy,Yes,The First People’s Hospital of Jingmen,Yes,Xiamen Wantai Kairui Biotechnology - Not available - Total Ig - Serum,Yes,0.9570000000000001,Mean,28.5 (seropositive); 28.1 (seronegative),201031_VillaCaldari_IstitutoZooprofilatticoSperimentaleDell’AbruzzoEdelMoliseGCaporale,352.0,"A study was performed in Villa Caldari, Italy, where members of the general population were invited to take part. Testing for antibodies revealed 10.9% seroprevalence in the population. ",Yes,335.0,,135,No,0.987,58.6 (seropositive); 47.3 (seronegative),Yes,IQR - interquartile range,Microorganisms,Cross-sectional survey ,https://dx.doi.org/10.3390/microorganisms8111711,Cito,rec0C0h4VXWWsjbCa,Moderate,cito_covid-19_2020,False,Wantai SARS-CoV-2 Total Ab ELISA,['Beijing Wantai Biological'],2021-01-22,2021-06-16,,,,,,"['Villa Caldari,Abruzzo']",,Members of the community from Villa Calderi were invited. ,,,Sex: Male ,0.14800000000000002,0.08199999999999999,,,,,,,,,
31,Validated by developers/manufacturers,,['Illinois'],All,Multiple groups,['IgG'],0.046,2020-06-30,634,Convenience,0.996,,201209_Chicago_NorthwesternUniversity_Asian,1.0,Serum,CLIA,29.0,2020-05-28,Health care workers and caregivers,Local,Asian,['Nucleocapsid (N-protein)'],Race,Cook County,2020-12-09,True,Journal Article (Peer-Reviewed),True,Yes,Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago,163,,Northwestern University ,Yes,Yes,United States of America,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Mean,12,201209_Chicago_NorthwesternUniversity,1330.0,"Researchers at Northwestern University tested 6510 health care workers for SARS-CoV-2 antibodies in Chicago, USA, and found a 5.3% adjusted seroprevalence. ",No,5180.0,,73,Yes,1.0,40.6,No,SD - standard deviation,Open forum infectious diseases,Cross-sectional survey ,https://dx.doi.org/10.1093/ofid/ofaa582,Wilkins,rec0CBRqQcGhUHauu,Moderate,wilkins_seroprevalence_2021-1,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2020-11-04,2021-06-16,,,,,,"['Chicago,Illinois']",,"All HCWs (employees and physician members of affiliated outpatient practices) were invited to join the study May 28, 2020-June 30, 2020",,,Race: Asian,0.065,0.031000000000000003,,,,,,,,,
32,Validated by developers/manufacturers,,['Hauts-de-France'],All,Multiple groups,['IgG'],0.028999999999999998,2020-06-02,1511,Stratified probability,1.0,15.0,210115_France_InstitutNationaldelaStatistiqueetdesÉtudesÉconomiques_Hauts-de-France,0.9440000000000001,Dried Blood,ELISA,65.0,2020-05-02,Household and community samples,Regional,Hauts-de-France,['Spike'],Geographical area,,2021-01-15,True,Institutional Report,,Yes,"In May 2020, 4.5% of the population of metropolitan France had developed antibodies against SARS-CoV-2",145,10.1093/clinchem/hvaa120,l’Institut national de la santé et de la recherche médicale (Inserm) ,Yes,Yes,France,Yes,Barnes Jewish Hospital Laboratory,Yes,EUROIMMUN AG - EI SARS-Cov-2 IgG assay - IgG - Serum,Yes,0.621,Groups,,210115_France_InstitutNationalDeLaSantéEtDeLaRechercheMédicale,5469.0,"Researchers at the l’Institut national de la santé et de la recherche médicale (Inserm) tested 12,114 members of the general population of France and found a 4.5% seroprevalence. ",No,6645.0,,64,No,0.948,"15-20 (n = 928)
21-29 (n = 1253) 
30-49 (n = 4072) 
50-64 (n = 3375) 
> 64 (n = 2486)
",Yes,,"Direction de la recherche, des études, de l'évaluation et des statistiques",Prospective cohort,https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-01/er1167-en.pdf,Warszawski,rec0CYydEWf6p3wCO,Low,josiane_warszawski_may_2021,True,"Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)",['EUROIMMUN AG'],2021-03-16,2021-06-16,,,,,,,,French general population,,True,,0.046,0.013000000000000001,,,,,,,,,
33,Validated by developers/manufacturers,48.0,,All,Adults (18-64 years),"['IgG', 'IgM']",0.0666,2020-06-14,30,Convenience,0.9770000000000001,23.0,200721_Egypt_CairoUniversity_Physician_Overall,0.934,Whole Blood,LFIA,2.0,2020-06-01,Health care workers and caregivers,Local,Physician,['NR'],Type of health care worker,,2020-07-21,True,Journal Article (Peer-Reviewed),True,No,SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility,48,10.1101/2020.04.22.20075564,Cairo University,No,Yes,Egypt,Yes,Department of Clinical Laboratory - Saitama Medical University,Unclear,Artron Laboratories Inc. - One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test - IgG; IgM - Serum,Yes,0.43200000000000005,Median,23-48,200721_Egypt_CairoUniversity,30.0,Al Manial University Hospital studied health care workers in Egypt and found a seroprevalence of 12.2%.,No,44.0,,60,No,1.0,32,No,Total Range,Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology,Cross-sectional survey ,https://dx.doi.org/10.1016/j.ajg.2020.07.005,Kassem,rec0CkuBO8L3ZwJfd,High,kassem_sars-cov-2_2020,False,One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test,['Artron Laboratories Inc.'],2020-09-29,2021-06-16,,,,,,['Cairo'],,"74 healthcare workers from the gastroenterology service of Al-Manial UniversityHospital, Cairo University
",,,Physicians,,,AND/OR,,,,,,,,
34,,,['\xa0Mississippi'],All,Multiple groups,"['Total Antibody', 'IgG']",0.084,2020-09-10,987,Stratified non-probability,,0.0,201124_USA_CDC_August/September3_Mississippi,,Serum,CLIA,,2020-08-26,Residual sera,Regional, Mississippi,"['Nucleocapsid (N-protein)', 'Spike']",Primary Estimate,,2020-11-24,True,Journal Article (Peer-Reviewed),True,No,Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.,,,CDC COVID-19 Response,Yes,No,United States of America,No,,Unclear,,Yes,,Groups,,201124_USA_CDC_August/September3_Mississippi,,"COVID-19 Response, US Centers for Disease Control and Prevention studied 177 919 serum samples to find a seroprevalence of 0-23.3% across 4 different time points",N/A,,,,Yes,,0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316),No,,JAMA internal medicine,Cross-sectional survey ,https://dx.doi.org/10.1001/jamainternmed.2020.7976,Bajema,rec0Cw3Myn134RcSL,Moderate,bajema_estimated_2020,False,"Elecsys® Anti‐SARS‐CoV‐2,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG","['Roche Diagnostics', ' Basel', ' Switzerland', 'Ortho Clinical Diagnostics Inc.', 'Abbott Laboratories']",2021-03-20,2021-06-16,Multiple tests used,True,True,True,,,,"Residual patient sera from specimens collected for routine screening (eg, cholesterol, thyroid) or clinical management by 2 commercial laboratories (laboratory A and laboratory B) across 50 US states, Washington DC, and Puerto Rico ",,True,,0.1273,0.0489,AND/OR,True,,,,,,,
35,Validated by independent authors/third party/non-developers,,['England'],All,Multiple groups,['Not reported'],0.779,2020-04-13,394,Convenience,,19.0,201101_London_PublicHealthEngland_Overall,0.9920000000000001,Serum,ELISA,307.0,2020-04-10,Assisted living and long-term care facilities,Local,Overall ,"['Nucleocapsid (N-protein)', 'Spike']",Primary Estimate,,2020-11-01,True,Journal Article (Peer-Reviewed),True,Yes,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19,,,Public Health England,No,Yes,The United Kingdom,Yes,,Unclear,,Unclear,,Groups,,201101_London_PublicHealthEngland,95.0,"Residents/staff in six long term care homes were screened for prevalence of SARS-CoV-2 antibodies, and a seroprevalence of 77.9% (n=394)",Yes,299.0,,,No,,19-39 (n=66); 40-59 (n=113); 60-79 (n=71); 80+ (n=144),No,,EClinicalMedicine,Prospective cohort,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30341-2/fulltext,Ladhani,rec0ENZITRlCGp9bR,High,ladhani_high_2020,False,Author designed (ELISA),,2021-03-05,2021-06-16,"Author designed or validated test, not in Finddx database",True,True,True,,"['London,England']",,LTC residents and healthcare workers,All seropositivity in cohort,,,0.8170000000000001,0.736,,,,,,,,,
36,Multiple tests with diff validations or values derived from each type,65.0,['Ohio'],All,Adults (18-64 years),"['IgG', 'IgM']",0.0,2020-05-19,27,Convenience,,22.0,201030_Cleveland_CaseWesternReserveUniversity_WhiteOther,,Serum,ELISA,0.0,2020-04-20,Essential non-healthcare workers,Local,"White, other",['NR'],Race,Cuyahoga,2020-10-30,True,Journal Article (Peer-Reviewed),True,Yes,SARS-CoV-2 Infection Among Serially Tested Emergency Medical Services Workers,97,,Case Western Reserve University,No,Yes,United States of America,Yes,University of California,Yes,"Epitope Diagnostics, Inc. - EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit; EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit - IgG; IgM - Plasma; Serum",Unclear,0.754,Mean,,201030_Cleveland_CaseWesternReserveUniversity,253.0,"Researchers at the Case Western Reserve University serosurveyed 296 first responders in Cleveland, USA, and found a 5.4% seroprevalence. ",Yes,42.0,,98,No,0.898,44.1,No,,Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors,Cross-sectional survey ,https://dx.doi.org/10.1080/10903127.2020.1831668,Tarabichi,rec0FOZN9IJyGL1Dc,High,tarabichi_sars-cov-2_2020,False,"EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit,EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit","['Epitope Diagnostics', ' Inc.']",2020-12-21,2021-06-16,,,,,,"['Cleveland,Ohio']",,First responders: EMS and Fire Dept,Positive testing was regarded as any positive SARS-CoV-2 PCR (at the revised threshold) or non-equivocally positive serological assay,,Race: Caucasian,,,AND/OR,,,,,,,,
37,Validated by independent authors/third party/non-developers,,['Pennsylvania'],Female,Adults (18-64 years),"['IgG', 'IgM']",0.0325,2020-06-03,400,Sequential,0.9890000000000001,,200729_Philadelphia_UniversityofPennsylvania_Asthma,1.0,Serum,ELISA,13.0,2020-04-04,Pregnant or parturient women,Local,Asthma,['Spike'],Comorbidities,Philadelphia,2020-07-29,True,Journal Article (Peer-Reviewed),True,Yes,SARS-CoV-2 Seroprevalence Among Parturient Women,,,University of Pennsylvania,Yes,Yes,United States of America,Yes,,Yes,,Unclear,,Median,27-35,200729_Philadelphia_UniversityofPennsylvania,0.0,University of Pennsylvania studied parturient women in Philadelphia and found a seroprevalence of 6.2%.,Yes,1293.0,,,No,,31,Yes,IQR - interquartile range,Science Immunology,Prospective cohort,https://immunology.sciencemag.org/content/5/49/eabd5709,Flannery,rec0FZvDr6C67OF3R,Moderate,flannery_sars-cov-2_2020-2,False,Author designed (ELISA),,2020-07-23,2021-06-16,"Author designed or validated test, not in Finddx database",True,,,834.0,"['Philadelphia,Pennsylvania']",15.0,"Parturient women;  pregnant women presenting for delivery from April 4 to June 3, 2020 at two academic birth hospitals in Philadelphia, Pennsylvania.

Asthma
","Possessed IgG or IgM SARS-CoV-2 specific antibodies

 >0.48 arbitrary units, which was subsequently used as the cutoff for defining seropositivity in the 2020 cohort.",,,,,AND/OR,,,,,,,,
38,Validated by independent authors/third party/non-developers,19.0,['England'],All,Children and Youth (0-17 years),['IgG'],0.061,2020-04-30,647,Stratified probability,0.991,1.0,200821_England_PHE_SeroepiUnitPaedsSurvey_Under20_TestAdj_April,0.9570000000000001,Serum,ELISA,43.0,2020-04-01,Residual sera,National,,['Nucleocapsid (N-protein)'],Primary Estimate,,2020-08-21,True,Institutional Report,True,Yes,PHE England week 34,163,,Public Health England,Yes,Yes,The United Kingdom,No,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Threshold,,200821_England_PHE_SeroepiUnitPaedsSurvey_2_April,,This report summarises the information from the surveillance systems which are used to monitor the Coronavirus Disease 2019 (COVID-19) pandemic in England. ,Unclear,,True,73,Yes,1.0,"<30
",Yes,,Public Health England,Repeated cross sectional study,https://www.gov.uk/government/publications/national-covid-19-surveillance-reports,Public Health England,rec0GrbYvwtOYHGN4,Moderate,public_health_england_national_2020-17,False,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2020-07-19,2021-06-16,,,True,,,,,Residual sera from children and young adults under 20 years from participating NHS and PHE laboratories across England (SEU and paediatric hospital collections) ," pos>=1.4
",,,0.084,0.040999999999999995,,True,56286961.0,56286961.0,150793.0,113365.0,94038.0,,
39,Validated by independent authors/third party/non-developers,,,Other,Multiple groups,['IgG'],0.027999999999999997,2020-07-31,41,Stratified probability,0.996,10.0,210120_Chennai_NationalInstituteOfEpidemiology_primary_transgender,1.0,Serum,CLIA,5.0,2020-07-01,Household and community samples,Local,,['Nucleocapsid (N-protein)'],Sex/Gender,,2021-01-20,True,Journal Article (Peer-Reviewed),,Yes,"Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India",163,,National Institute of Epidemiology,Yes,Yes,India,Yes,"Department of Laboratory Medicine, National University Hospital, Singapore",Yes,Abbott Laboratories - Abbott Architect SARS-CoV-2 IgG - IgG - Serumabb,Yes,0.41200000000000003,Mean,17.3,210120_Chennai_NationalInstituteOfEpidemiology,5785.0,National Institute of Epidemiology studied the general population (n = 12405) in Chennai and found 18.4% seroprevalence,Unclear,6493.0,,73,Yes,1.0,41.1,Yes,SD - standard deviation,Emerging infectious diseases,Cross-sectional survey ,https://dx.doi.org/10.3201/eid2702.203938,Selvaraju,rec0Gz2WjX0OaLXGZ,Low,selvaraju_population-based_2021,True,Abbott Architect SARS-CoV-2 IgG,['Abbott Laboratories'],2021-02-21,2021-06-16,,,,,,['Chennai'],,We conducted a household-based cross-sectional sur- vey among usual residents >10 years of age in GCC.,The presence of antibody level above the cutoff index value >1.4 was interpreted as positive.,True,Sex: Unknown/Other,0.273,0.0,,True,,,,,,,
40,,,"['New Mexico', ' Montana', ' Wyoming', ' Colorado', ' Texas', ' North Dakota', ' Louisiana', ' Nevada', ' Tennessee', ' Arizona', ' South Dakota', ' California', ' Washington', ' Missouri']",All,Seniors (65+ years),"['IgA', 'IgG', 'IgM', 'Total Antibody']",0.011200000000000002,2020-07-31,357,Sequential,,86.0,200918_UnitedStates_Vitalant_>85,,Serum,CLIA,4.0,2020-06-01,Blood donors,National,>85 years,['Spike'],Age,,2020-09-18,True,Preprint,True,No,Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors,488,,Vitalant,Yes,Yes,United States of America,Yes,Public Health England,Unclear,Ortho Clinical Diagnostics - VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total - Total Ig - Serum,Unclear,0.85,Groups,,200918_UnitedStates_Vitalant,90131.0,"A large blood center began testing for antibodies against SARS-CoV-2 across the US, and a seroprevalence of 1.83% among the 252882 blood donors was reported. ",N/A,99525.0,,85,No,0.9940000000000001,16-17 (n=1812); 18-29 (n=22048); 30-39 (n=30956); 40-49 (n=34151); 50-64 (n=66030); 65-74 (n=28453); 75-84 (n=5848); >85 (n=357),Yes,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1.full.pdf,Vassallo,rec0H6360YxKlOJ1c,Moderate,vassallo_seroprevalence_2020,False,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,['Ortho Clinical Diagnostics Inc.'],2020-10-13,2021-06-16,,,,,,,,,Unique individuals who test positive for SARS-CoV-2,,,,,AND/OR,,,,,,,,
41,Validated by independent authors/third party/non-developers,,,Male,Multiple groups,['IgG'],0.0487,2020-08-13,46269,Simplified probability,0.986,18.0,201027_England_ImperialCollegeLondon_SamplingPeriod2_Male ,0.8440000000000001,Whole Blood,LFIA,2117.0,2020-07-31,Household and community samples,National,Male ,['Spike'],Sex/Gender,,2020-10-27,True,Preprint,True,Yes,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",,,Imperial College London,Yes,Yes,The United Kingdom,Yes,,Unclear,,No,,Groups,,201027_England_ImperialCollegeLondon_SamplingPeriod2,46269.0,"Imperial College London studied community samples of adults at three different time points in England, UK and found seroprevalences of 6.0% in those sampled between July 31 - April 13.",No,59560.0,,,Yes,,18-24 (n= 6493); 25-34 (n= 13573); 35-44 (n=17130); 45-54 (n=21487); 55-64 (n=21840); 65-74 (n=17617); 75+ (n=7689),Yes,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full.pdf,Ward,rec0IscBnTfQ9ZGH0,Moderate,ward_declining_2020,False,Coronavirus Antigen Rapid Test,['Fortress Diagnostics'],2021-01-22,2021-06-16,Commercially available but not in the Finddx database ,True,,,,,49.0,,Total antibody positive,True,Sex: Male ,0.051100000000000007,0.0464,,True,,,,,,,
42,,29.0,['California'],All,Adults (18-64 years),['IgG'],0.0581,2020-08-31,172,Unclear,,20.0,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW_age20-29,,Serum,ELISA,10.0,2020-04-08,Health care workers and caregivers,Local,20-29,['Spike'],Age,Los Angeles,2020-11-21,True,Preprint,True,Yes,"Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California",,,University of California Los Angeles,Yes,Yes,United States of America,Yes,,Yes,,Unclear,,Groups,,201121_LosAngeles_UniversityofCaliforniaLosAngeles_HCW1,312.0,The University of California Los Angeles studied 1108 healthcare workers in Los Angeles and found 3.9% seroprevalence,Unclear,710.0,,,No,,"20-29 (n = 172) 
30-39 (n = 418)
40-49 (n = 235)
50-59 (n = 148)
60+ (n = 55)",Unclear,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2020.11.18.20234211v1,Halbrook,rec0JOqyhwJNQkRE6,Moderate,halbrook_incidence_2020,False,Not reported/ Unable to specify,,2021-01-21,2021-06-16,"Author designed or validated test, not in Finddx database",True,,,,,,Health system workers (HSW) employed by UCLA Health—including those with and without direct patient care responsibilities,,,,,,,,,,,,,,
43,Validated by developers/manufacturers,69.0,['Colorado'],All,Adults (18-64 years),['IgG'],0.04,2020-08-15,125,Convenience,0.986,20.0,201203_AraphoeCounty_UniversityofColorado_Sheriff'sOffice/PoliceDepartment,0.85,Serum,ELISA,5.0,2020-07-15,Essential non-healthcare workers,Local,Worked in Sheriff's office or Police Dept.,"['Nucleocapsid (N-protein)', 'Spike']",Occupation,Araphoe County,2020-12-03,True,Journal Article (Peer-Reviewed),True,Yes,Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders - the COVID-19 Arapahoe SErosurveillance Study (CASES) Project.,,,University of Colorado,No,Yes,United States of America,Yes,,Unclear,,No,,Median,32-48,201203_AraphoeCounty_UniversityofColorado,121.0,"Resarchers at the University of Colorado surveyed 264 first responders in Araphoe County, Colorado USA and found a 4% seroprevalence. ",Unclear,143.0,,,No,,38,No,IQR - interquartile range,Journal of occupational and environmental medicine,Cross-sectional survey ,https://pubmed.ncbi.nlm.nih.gov/33298759/,Sabourin,rec0JVaAdwFuPjzqE,High,sabourin_risk_2020,False,,['Exsera BioLabs'],2021-02-27,2021-06-16,Commercially available but not in the Finddx database ,True,,,1000.0,,100.0,First responders," To be considered seropositive, antibodies to both the spike RBD and nucleocapsid of SARS-CoV-2 had to be detected.",,,,,,,,,,,,,
44,Validated by developers/manufacturers,,['Brandenburg'],All,Adults (18-64 years),['Total Antibody'],0.0333,2020-07-31,30,Convenience,0.998,,200929_Oberspreewald-Lausitz_BrandenburgUniversityofTechnologyCottbus-Senftenberg_HCW_VeryHighRisk,0.995,Serum,CLIA,1.0,2020-07-01,Health care workers and caregivers,Local,"Very-High Risk Group - emergency room, intensive care medicine - nurses, physicians, therapists",['Nucleocapsid (N-protein)'],Exposure level granular,,2020-09-29,True,Preprint,True,Yes,Testing the backbone of the healthcare system: a prospective serological-epidemiological cohort study of healthcare workers in rural Germany,,,Brandenburg University of Technology Cottbus-Senftenberg,No,Yes,Germany,Yes,,Unclear,,Yes,,Mean,11.6 (very-high-risk group); 11.91 (high-risk group); 10.9 (medium risk group); 8.5 (low-risk group),200929_Oberspreewald-Lausitz_BrandenburgUniversityofTechnologyCottbus-Senftenberg,21.0,"Brandenburg University of Technology Cottbus-Senftenberg studied health care workers in a standard care hospital in Oberspreewald-Lausitz, Germany and found a seroprevalence of 1.3%.",Unclear,135.0,,,No,,42.7 (very-high-risk group); 46.77 (high-risk group); 44.7 (medium risk group); 45.6 (low-risk group),No,SD - standard deviation,Research Square,Prospective cohort,https://doi.org/10.21203/rs.3.rs-84703/v1,Hoffmann,rec0JZFtOHr4y9YMU,High,hoffmann_testing_2020,False,Author designed (ELISA),,2020-11-28,2021-06-16,"Author designed or validated test, not in Finddx database",True,,,10453.0,"['Oberspreewald-Lausitz,Brandenburg']",185.0,"nurses, physicians, therapists, radiology, lab assistants, service and administration staff",cutoff index >= 1,,,,,,,,,,,,,
45,Validated by independent authors/third party/non-developers,,['Piemonte'],All,Adults (18-64 years),['IgG'],0.06944444444,2020-05-20,216,Convenience,0.985,,201006_Turin_UniversityofTorino_TechnicalPersonnel,0.9790000000000001,Serum,CLIA,15.0,2020-04-17,Health care workers and caregivers,Local,Technical Personnel,['Spike'],Type of health care worker,,2020-10-06,True,Journal Article (Peer-Reviewed),True,Yes,"Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy",,10.1101/2020.06.15.20131672,University of Torino,Yes,Yes,Italy,Yes,"Institut für Infektionsmedizin, Christian-Albrechts-Universität und Universitätsklinikum Schleswig-Holstein",Unclear,DiaSorin SpA - LIAISON® SARS-CoV-2 S1/S2 IgG - IgG - Serum,Yes,0.8079999999999999,Mean,10.6,201006_Turin_UniversityofTorino,1376.0,"University of Torino studied health care workers from the Torino region of Italy (n= 5,444) and found a seroprevalence of 6.9%.",Yes,4068.0,,,No,0.96,49.4 ,No,SD - standard deviation,Emerging infectious diseases,Cross-sectional survey ,https://dx.doi.org/10.3201/eid2701.203027,Calcagno,rec0JgCMGhgYzEMY3,Moderate,calcagno_risk_2021,False,Liaison SARS-CoV-2 S1/S2 IgG,['DiaSorin SpA'],2021-02-13,2021-06-16,,,,,,"['Torino (Turin),Piemonte']",,,S1/S2 SARS-CoV-2 antibodies found ,,,,,,,,,,,,,
46,Validated by developers/manufacturers,,['West Bengal'],All,Multiple groups,['IgG'],0.0,2020-08-08,15,Stratified probability,0.981,,200914_PaschimMedinipur_MedicalCollegeKolkata_Chandrakona,0.983,Serum,ELISA,0.0,2020-07-26,Household and community samples,Regional,Chandrakona Municipality,['NR'],Geographical area,Paschim Midinipur,2020-09-14,True,Preprint,True,Yes,"Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College &",,,Medical College Kolkata,No,Yes,India,Yes,,Yes,,Yes,,Groups,,200914_PaschimMedinipur_MedicalCollegeKolkata,287.0,"Researchers at the Medical College Kolkata, India, tested the asymptomatic general population of Paschim Medinipur District and found a 4.15% SARS-CoV-2 antibody seroprevalence. ",Unclear,171.0,,,No,,0-5 (n=1); 11-19 (n=28); 20-45 (n=290); 46-59 (n=101); 60 and above (n=38),Yes,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1,Satpati,rec0KGlFZyaCS53PE,Moderate,satpati_sero-surveillance_2020,True,ErbaLisa COVID-19 IgG ELISA Kit,['Calbiotech Inc.'],2020-11-05,2021-06-16,Commercially available but not in the Finddx database ,True,,,,"['Chandrakona,West Bengal']",,"General population of Paschim Medinipur District, West Bengal, India",IgG positivity,,,,,,,,,,,,,
47,Validated by developers/manufacturers,78.0,['Baden-Württemberg'],Female,Multiple groups,['IgG'],0.0449,2020-08-06,89,Sequential,0.998,18.0,201216_Heidelberg_UniversityHospitalHeidelberg_female,0.946,Serum,ELISA,4.0,2020-05-05,Patients seeking care for non-COVID-19 reasons,Local,,['NR'],Sex/Gender,,2020-12-16,True,Journal Article (Peer-Reviewed),True,No,SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study,145,10.1093/clinchem/hvaa120,University Hospital Heidelberg,No,Yes,Germany,Yes,Barnes Jewish Hospital Laboratory,Unclear,EUROIMMUN AG - EI SARS-Cov-2 IgG assay - IgG - Serum,Yes,0.621,Median,18.1-78.2,201216_Heidelberg_UniversityHospitalHeidelberg,130.0,The University of Heidelberg studied liver transplat recipients (n = 219) at their facility and found 3.25 seroprevalence,Unclear,89.0,,64,No,0.948,56.9,No,Total Range,Transplantation Proceedings,Cross sectional study with prospective cohort follow up of a subset of the sample,https://www.sciencedirect.com/science/article/abs/pii/S0041134520329043?via%3Dihub,Rauber,rec0KPc1olF5hXGrK,High,rauber_sars-cov-2_2020,False,"Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)",['EUROIMMUN AG'],2021-04-22,2021-06-16,,,,,,"['Heidelberg,Baden-Württemberg']",,Patients who have underwent a liver transplant.,,,Sex: Female,,,,,,,,,,,
48,Validated by developers/manufacturers,,['Uttar Pradesh'],All,Adults (18-64 years),"['IgM', 'IgA', 'IgG', 'Total Antibody']",0.3,2020-10-31,100,Simplified probability,0.99,,210411_India_BanarasHinduUniversity_Mirzapur,1.0,Multiple Types,,30.0,2020-10-01,Household and community samples,Local,Mirzapur,['Not reported'],Geographical area,Mirzapur,2021-04-11,True,Preprint,,,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,,,Banaras Hindu University,,,India,,,,,,,,,210411_India_BanarasHinduUniversity,,Researchers at the Banaras Hindu University studied 2310 healthy working individuals in India and found a 30.55% seroprevalence. ,,,,,,,,,,medRxiv,Cross-sectional survey ,https://www.medrxiv.org/content/10.1101/2021.02.05.21251118v2,Singh,rec0KpRI0mV2icc0f,Moderate,singh_estimation_2021,False,Coviscreen kittotal antibody (IgM+IgA+IgG),"['Biosense Technologies', ' India']",2021-04-14,2021-06-16,,,,,,,,Healthy working population. Targeted high-exposure jobs. ,,,,0.396,0.219,AND/OR,,,,,,,,
49,Validated by developers/manufacturers,29.0,['West Bengal'],All,Adults (18-64 years),['IgG'],0.11813000000000001,2020-08-23,364,Stratified probability,1.0,,201109_Kokalta_ApolloGleneaglesHospitals_HCW_Age_<30,0.9,Serum,CLIA,43.0,2020-07-12,Health care workers and caregivers,Local,<30 years,['Spike'],Age,,2020-11-09,True,Journal Article (Peer-Reviewed),True,Yes,Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,488,,Apollo Gleneagles Hospitals,Yes,Yes,India,Yes,Diagnostic Support Group (DSP) at PHE Porton,Unclear,Ortho Clinical Diagnostics Inc. - VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 IgG - IgG - Serum,Yes,0.774,Groups,,201109_Kokalta_ApolloGleneaglesHospitals,734.0,Researchers at Apollo Gleneagles Hospitals studied 1122 HCW to find a seroprevalence of 11.94%,No,388.0,,72,No,0.996,<30 (n=364); 30-50 (n=665); >50 (n=93),Yes,,The Journal of the Association of Physicians of India,Cross-sectional survey ,https://www.japi.org/x264a444/seroprevalence-of-covid-19-amongst-health-care-workers-in-a-tertiary-care-hospital-of-a-metropolitan-city-from-india,Goenka,rec0LDnRJbxzLfTXV,Moderate,goenka_seroprevalence_2020,False,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,['Ortho Clinical Diagnostics Inc.'],2021-01-18,2021-06-16,,,,,,"['Kolkata,West Bengal']",,HCW of a large tertiary care hospital in India (Apollo Gleneagles Hospitals),positive for IgG antibodies,,,,,,,,,,,,,
